Transient cerebal ischaemic attack

Active Ingredient: Warfarin

Indication for Warfarin

Population group: only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

1-10 mg once daily

Route of admnistration

Oral

Defined daily dose

1 - 10 mg

Dosage regimen

From 1 To 10 mg once every day

Loading dose

10 mg

Detailed description

Adults

Whenever possible, base-line prothrombin time should be determined before the initial dose is given. An initial loading dose for warfarin is usually 10 mg daily for adults, tailored to individual requirements for the desired degree of anticoagulant effect. The maintenance dose is usually started after 48 hours and depends upon the prothrombin time-reported as international normalised ratio (INR). Currently recommended ranges of therapeutic anticoagulation are the following:

Prophylaxis of deep-vein thrombosis including surgery in high risk patients: INR 2-2.5.

Prophylaxis in hip surgery and fractured femur operations, treatment of deep vein thrombosis, pulmonary and systemic embolism, prevention of venous thromboembolism in myocardial infarction, transient ischaemic attacks, mitral stenosis with embolism, tissue prosthetic heart valves: INR 2-3.

Recurrent deep-vein thrombosis and pulmonary embolism, mechanical prosthetic heart valves, arterial disease including myocardial infarction: INR 3-4.5.

The daily maintenance dose, taken at the same time each day, is usually between 3 mg and 9 mg. In the early days of treatment, INR should be determined daily or on alternative days, then, depending on response, determinations should be at longer intervals and then, up to every 8 weeks.

In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together. Concomitant therapy with heparin affects the results of control tests and should be discontinued at least six hours before the test is first carried out.

Elderly

The elderly may be more susceptible to the effects of warfarin, resulting in increased risk of haemorrhage. Lower maintenance doses, weight for weight, than those usually recommended for adults may be required for these patients.

Active ingredient

Warfarin

Warfarin is a synthetic 4-Hydroxycoumarin derivative which acts by preventing the formation of active procoagulation factors II, VII, IX and X in the liver by inhibiting the vitamin K – mediated gammacarboxylation of precursor proteins. Full therapeutic activity is not achieved until circulating coagulation factors have been removed by normal catabolism. This occurs at different rates for each factor, with factor VII having the shortest half-life. Warfarin has no direct thrombolytic effect, though it may limit the extension of existing thrombi.

Read more about Warfarin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.